Stoke Therapeutics (STOK) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$0.65.

  • Stoke Therapeutics' EPS (Weighted Average and Diluted) fell 3829.79% to -$0.65 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.68, marking a year-over-year increase of 13238.1%. This contributed to the annual value of -$1.64 for FY2024, which is 3107.19% up from last year.
  • Latest data reveals that Stoke Therapeutics reported EPS (Weighted Average and Diluted) of -$0.65 as of Q3 2025, which was down 3829.79% from -$0.4 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $1.9 in Q1 2025 and a low of -$0.69 during Q2 2023
  • For the 4-year period, Stoke Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.39, with its median value being -$0.57 (2024).
  • Over the last 5 years, Stoke Therapeutics' EPS (Weighted Average and Diluted) had its largest YoY gain of 43333.33% in 2025, and its largest YoY loss of 3829.79% in 2025.
  • Quarter analysis of 4 years shows Stoke Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.65 in 2022, then rose by 5.59% to -$0.61 in 2023, then soared by 67.77% to -$0.2 in 2024, then plummeted by 228.61% to -$0.65 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.65 for Q3 2025, versus -$0.4 for Q2 2025 and $1.9 for Q1 2025.